


The Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place on 30 September 2026, will bring together experts from across the drug discovery ecosystem to examine the scientific, operational and commercial developments shaping the future of early-stage drug discovery. Following the announcement of the preliminary speaker lineup, we… Read More

Insilico Medicine has introduced biological age as a core condition in virtual cell research with the launch of its Virtual Aging Cell (VAC) Webpage and a preview of its Multi-Agent driven VAC platform. The clinical-stage drug discovery company said the platform represents the industry’s first multi-agent Virtual Aging Cell platform… Read More

Join this webinar, hosted by DDW and supported by Cytiva to learn how automation, parallel chromatography, and smart software features can help scientists increase throughput, reduce hands-on time, and maintain consistent purification performance. Join for free on Tuesday, September 15 to learn: How parallel chromatography can be used to process… Read More

As sample numbers increase in early-stage development, purification can quickly become a bottleneck. This webinar, hosted by DDW and supported by Cytiva, explores how automation, parallel chromatography, and smart software features can help scientists increase throughput, reduce hands-on time, and maintain consistent purification performance. Learn how multiple chromatography systems can… Read More

Daniel Delubac, Chief Executive Officer at iOrganBio looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models. The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes of Health (NIH) announced a $150 million investment to support the development of novel approaches that mimic human biology to reduce… Read More

Researchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects. Scientists at The Institute of Cancer Research, London, and The University of Edinburgh, discovered that blocking the TUT4/7 enzymes can significantly halt… Read More

Infinitopes has announced that the first patient has been dosed with ITOP1, the company’s lead investigational therapeutic cancer vaccine candidate. This marks the first clinical evaluation of Infinitopes’ Precision Immunomics platform, which combines large-scale immunopeptidomic antigen discovery with engineered viral vector technologies, to identify naturally presented tumour antigens capable of generating durable anti-tumour T-cell responses. Read More

News round-up for 10-14 August by Diana Turner, Content Team at DDW. This week’s news round-up highlights new discoveries in cancer research, including the first trial of a new type of immunotherapy, an immune cell finding that could transform cancer treatment, and a groundbreaking drug… Read More

News round-up for 3-7 August by Diana Turner, Content Team at DDW. This week’s news round-up highlights new clinical trial results that demonstrate positive outcomes in Parkinson’s, colorectal cancer and Bundibugyo ebolavirus, as well as the first ever trial of a fridge-free vaccine. Elsewhere,… Read More

News round-up for 27-31 July by Megan Thomas, Content Team at DDW. This week’s news roundup centres around investment, innovation and strategic growth, which have dominated this week’s headlines. Across the drug discovery sector, companies have secured funding, expanded R&D capabilities and accelerated the adoption of AI-driven… Read More

The US Food and Drug Administration (FDA) has granted Fast Track Designation for HAYA Therapeutics’ HTX-001 for the treatment of symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The first-in-class investigational long non-coding RNA (lncRNA)-targeting therapy is in a Phase Ia/b trial, with the first cohort dosed this past May. HTX-001 is a… Read More

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases. Existing investors Hargreave Hale… Read More

We are pleased to announce the preliminary speaker lineup for the Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place 30 September 2026. Supported by DDW, the forum brings together senior leaders from biotech, pharma, academia, and investment to explore the opportunities and challenges shaping early-stage drug discovery. Running… Read More

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More